Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3

Conditions

Melanoma 300Carcinoma, Non-Small-Cell Lung 80Squamous Cell Carcinoma of Head and Neck 59Carcinoma, Renal Cell 58Neoplasms 40Neoplasm Metastasis 36Colorectal Neoplasms 36Stomach Neoplasms 29Carcinoma, Merkel Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 28Carcinoma, Transitional Cell 27Uterine Cervical Neoplasms 24Skin Neoplasms 24Head and Neck Neoplasms 24Lung Neoplasms 22Breast Neoplasms 21Carcinoma, Hepatocellular 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 18Pancreatic Neoplasms 16Uveal Melanoma 14Small Cell Lung Carcinoma 14Sarcoma 14Urinary Bladder Neoplasms 12Lymphoma 11Kidney Neoplasms 11Endometrial Neoplasms 11Brain Neoplasms 11Prostatic Neoplasms 10

Interventions

fludarabine phosphate 23Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 20Whole-Body Irradiation 18Mycophenolic Acid 16Cyclosporine 15Etoposide 11Tacrolimus 10Busulfan 10Antilymphocyte Serum 10Methotrexate 9Melphalan 9Bortezomib 9Vorinostat 6Rituximab 6Filgrastim 6Doxorubicin 6Vincristine 5Therapeutics 5Prednisone 5Lenalidomide 5tanespimycin 4Sirolimus 4Radiotherapy 4Psychiatric Rehabilitation 4Methylprednisolone 4Everolimus 4Carboplatin 4pembrolizumab 3Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × pembrolizumab × Dermatologic × Clear all
NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

City of Hope Medical Center

Phase 1/2 Active not recruiting
13 enrolled 12 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Withdrawn
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡